• What is MYD88?
  • MYD88 in Waldenstrom Macroglobulinemia
  • Clinical Trials


Myeloid differentiation primary response 88 (MYD88) is a gene that encodes a cytosolic adapter protein necessary for both innate and adaptive immune response. Missense mutations, nonsense mutations, silent mutations, and in-frame deletions are observed in cancers such as leukemias, lung cancer, and skin cancer.

Related Pathways

Last Updated: December 4, 2015

MYD88 in Waldenstrom Macroglobulinemia

MYD88 is mutated in 90–95% of Waldenstrom Macroglobulinemia patients (Growkova et al. 2017; Treon et al. 2011) with the predominant mutation being an L265P mutation. There are ongoing efforts to target MYD88 L265P as it has been defined as an early oncogenic event in the development of WM (Jimenez et al. 2013; Mori et al. 2013; Varettoni et al. 2013).

Last Updated: February 26, 2018

My Cancer Genome has released its new and improved cancer clinical trials search tool on our beta website. Please visit beta.padiracinnovation.org to check it out!

Disclaimer: The information presented at padiracinnovation.org is compiled from sources believed to be reliable. Extensive efforts have been made to make this information as accurate and as up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed. Despite our best efforts, this information may contain typographical errors and omissions. The contents are to be used only as a guide, and health care providers should employ sound clinical judgment in interpreting this information for individual patient care.